Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid-Sparing Agent

Volume: 27, Issue: 12, Pages: 1348 - 1358
Published: Dec 1, 2021
Abstract
Cardiac sarcoidosis (CS) is a major cause of morbidity and mortality in patients with systemic sarcoidosis. Steroid-sparing agents are increasingly used, despite a lack of randomized trials or published guidelines to direct treatment.This retrospective study included 77 patients with CS treated with prednisone monotherapy (n = 32) or a combination with mycophenolate mofetil (n = 45) between 2003 and 2018. Baseline characteristics and clinical...
Paper Details
Title
Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid-Sparing Agent
Published Date
Dec 1, 2021
Volume
27
Issue
12
Pages
1348 - 1358
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.